Development of a novel berberine-mediated mitochondria-targeting nano-platform for drug-resistant cancer therapy

Tuo, Jue; Xie, Yanqi; Song, Jia; Chen, Yizhen; Guo, Qin; Liu, Xin; Ni, Xiaoling; Xu, Dongling; Huang, Huizhi; Yin, Sheng; Zhu, Wenbo; Wu, Jun; Hu, Haiyan

doi:10.1039/c6tb01730d

Cited by 41 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, increasing evidence has demonstrated that PDT, a two-stage treatment that combines light energy with a drug (photosensitizer), is significantly effective against different types of cancers [34], including malignant brain tumors [8,9,35,36]. Importantly, in the search for novel photosensitizing agents, the natural plant-derived alkaloid BBR has demonstrated a broad spectrum of efficacy [37][38][39] as well as in conjunction with PDT anticancer schemes [19].…”

Section: Discussionmentioning

confidence: 99%

Berberine Photo-Activation Potentiates Cytotoxicity in Human Astrocytoma Cells through Apoptosis Induction

Morra

Martinelli

Gabriele

et al. 2021

JPM

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has recently attracted interest as an innovative and adjuvant treatment for different cancers including malignant gliomas. Among these, Glioblastoma (GBM) is the most prevalent neoplasm in the central nervous system. Despite conventional therapeutic approaches that include surgical removal, radiation, and chemotherapy, GBM is characterized by an extremely poor prognosis and a high rate of recurrence. PDT is a physical process that induces tumor cell death through the genesis and accumulation of reactive oxygen species (ROS) produced by light energy interaction with a photosensitizing agent. In this contribution, we explored the potentiality of the plant alkaloid berberine (BBR) as a photosensitizing and cytotoxic agent coupled with a PDT scheme using a blue light source in human established astrocytoma cell lines. Our data mainly indicated for the combined BBR-PDT scheme a potent activation of the apoptosis pathway, through a massive ROS production, a great extent of mitochondria depolarization, and the sub-sequent activation of caspases. Altogether, these results demonstrated that BBR is an efficient photosensitizer agent and that its association with PDT may be a potential anticancer strategy for high malignant gliomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Berberine Photo-Activation Potentiates Cytotoxicity in Human Astrocytoma Cells through Apoptosis Induction

Morra

Martinelli

Gabriele

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…Different liposomal vehicles such as positively charged liposomes containing phosphatidyl ethanolamine (PE), cholesterol, stearylamine and lipophilic cationic drug/molecule, TPP modified liposomes loaded with chlorin e6 (Ce6) and IR780 iodide, stearyl TPP-modified liposomal cargo, TPPpolyethylene glycol (PEG)-PE-modified liposomal cargo, TPP-cerosomes (Si-O-Si)-liposomal drug, PEGylated liposomes conjoined with 9-C16 berberine and folate have been utilized to treat against diseases for mitochondrial deliveries. 6,[122][123][124][125][126][127][128] Liposomal MITO-Porter containing mitochondrial fusogenic lipid envelops modified with R8, dual function (DF) MITO-Porter with mitochondrial signal peptide, stearyl modified S2 peptide decorated to DF-MITO-Porter, and R8/GALA modified MITO-Porter have been used to release cargos and target mitochondrial matrix through membrane fusion endocytic mechanism. 86,[129][130][131][132][133] Besides nucleic acids, coenzyme Q10-MITO-Porter also have been treated for mitochondrial delivery against ischemic/reperfusion injury.…”

Section: Liposomesmentioning

confidence: 99%

Mitochondrial targeting of potent nanoparticulated drugs in combating diseases

Mandal

2022

J Biomater Appl

View full text Add to dashboard Cite

Mitochondrial dysfunction, characterized by the electron transport chain (ETC) leakage and reduced adenosine tri-phosphate synthesis, occurs primarily due to free radicals -induced mutations in either the mitochondrial deoxyribonucleic acid (mtDNA) or nuclear (n) DNA caused by pathogenic infections, toxicant exposures, adverse drug-effects, or other environmental exposures, leading to secondary dysfunction affecting ischemic, diabetic, cancerous, and degenerative diseases. In these concerns, mitochondria-targeted remedies may include a significant role in the protection and treatment of mitochondrial function to enhance its activity. Coenzyme Q10 pyridinol and pyrimidinol antioxidant analogues and other potent drug-compounds for their multifunctional radical quencher and other anti-toxic activities may take a significant therapeutic effectivity for ameliorating mitochondrial dysfunction. Moreover, the encapsulation of these bioactive ligands-attached potent compounds in vesicular system may enable them a superb biological effective for the treatment of mitochondria-targeted dysfunction-related diseases with least side effects. This review depicts mainly on mitochondrial enzymatic dysfunction and their amelioration by potent drugs with the usages of nanoparticulated delivery system against mitochondria-affected diseases.

show abstract

“…It is well-known that mitochondria also contain DNA (mtDNA), and these double-stranded circular DNA molecules take charge of the synthesis of tens of proteins . Thus, mitochondria should be another critical target for chemotherapy, and delivering DNA toxins into mitochondria is another wise choice toward enhanced chemotherapy. ,− …”

Section: Mitochondria-targeted Therapymentioning

confidence: 99%

Boosting Cancer Therapy with Organelle-Targeted Nanomaterials

Gao

Pan

et al. 2019

ACS Appl. Mater. Interfaces

184

119

View full text Add to dashboard Cite

The ultimate goal of cancer therapy is to eliminate malignant tumors while causing no damage to normal tissues. In the past decades, numerous nanoagents have been employed for cancer treatment because of their unique properties over traditional molecular drugs. However, lack of selectivity and unwanted therapeutic outcomes have severely limited the therapeutic index of traditional nanodrugs. Recently, a series of nanomaterials that can accumulate in specific organelles (nucleus, mitochondrion, endoplasmic reticulum, lysosome, Golgi apparatus) within cancer cells have received increasing interest. These rationally designed nanoagents can either directly destroy the subcellular structures or effectively deliver drugs into the proper targets, which can further activate certain cell death pathways, enabling them to boost the therapeutic efficiency, lower drug dosage, reduce side effects, avoid multidrug resistance, and prevent recurrence. In this Review, the design principles, targeting strategies, therapeutic mechanisms, current challenges, and potential future directions of organelle-targeted nanomaterials will be introduced.

show abstract

Development of a novel berberine-mediated mitochondria-targeting nano-platform for drug-resistant cancer therapy

Abstract: A novel berberine-mediated mitochondria-targeting nano-platform was constructed to inhibit tumor growth and bypass the multi-drug resistance problem by targeting doxorubicin to mitochondria of tumor cells.

Cited by 41 publications

References 30 publications

Berberine Photo-Activation Potentiates Cytotoxicity in Human Astrocytoma Cells through Apoptosis Induction

Berberine Photo-Activation Potentiates Cytotoxicity in Human Astrocytoma Cells through Apoptosis Induction

Mitochondrial targeting of potent nanoparticulated drugs in combating diseases

Boosting Cancer Therapy with Organelle-Targeted Nanomaterials

Contact Info

Product

Resources

About